Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects [Yahoo! Finance]
Aligos Therapeutics, Inc. - Common stock (ALGS)
Company Research
Source: Yahoo! Finance
Aligos anticipates dosing the first subject in Q2 2024 with topline safety and efficacy data expected in Q4 2024 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S. “ALG-055009 has enhanced potency, greater beta selectivity, and a favorable PK profile. We believe that these optimized pharmacologic properties may result in improved therapeutic outcomes for patients living with MASH. The initiation of the HERALD study is an important next step in achieving our goal to create a best-in-class thyroid hormone receptor beta agonist,” stated Lawrence Blatt, Ph.D., MB
Show less
Read more
Impact Snapshot
Event Time:
ALGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALGS alerts
High impacting Aligos Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ALGS
News
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyGlobeNewswire
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD [Yahoo! Finance]Yahoo! Finance
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDGlobeNewswire
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024GlobeNewswire
ALGS
Earnings
- 3/12/24 - Beat
ALGS
Sec Filings
- 4/16/24 - Form PRE
- 3/12/24 - Form S-8
- 3/12/24 - Form 10-K
- ALGS's page on the SEC website